SynthesisGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2025
The Paul Glaucoma Implant: a systematic review of safety, efficacy, and emerging applications.
Synthesis in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Paul glaucoma implant extrusion following post-surgical scleritis in patients with uveitic glaucoma: A case series.American journal of ophthalmology case reports · 2026Article
- Minimal effective plate: rethinking plate size in glaucoma drainage devices.Eye (London, England) · 2026Article
- From Fabrication to Function: Scalable Spray-Assisted Layer-by-Layer Films for Drug Delivery in Glaucoma.International journal of molecular sciences · 2026Article
- Comparative In Vitro Evaluation of Tube Resistance in Glaucoma Drainage Devices with Intraluminal Polypropylene Threads.Bioengineering (Basel, Switzerland) · 2026Article
- Outcomes of the Paul Glaucoma Implant in an Ambispective Multicenter Study: 12-Month Follow-Up.Biomedicines · 2026Article
- Reply to "Diplopia following PAUL implantation in the superotemporal quadrant - an underrecognized but severe complication".Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Article
- Severe Permanent Visual Decline After Hypotony-Induced Retinal Pigment Epithelial Changes.Cureus · 2025Article
- Predictive factors for the success of the Paul glaucoma implant: a one-year multicenter prospective study.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe Paul Glaucoma Implant (PGI) is a novel non-valved glaucoma drainage device designed to lower intraocular pressure (IOP) in patients with refractory glaucoma. This systematic review aims to evaluate the current evidence on safety, efficacy, and emerging applications of PGI implantation.
methodsA systematic literature search was conducted following PRISMA guidelines across PubMed/Medline, Embase, Cochrane, Google Scholar, and Web of Science databases up to April 2025. Quality assessment was performed using the NIH Quality Assessment Tool for Before-After Studies. Data on patient demographics, surgical techniques, IOP outcomes, success rates, and complications were extracted and analyzed.
resultsEighteen studies (946 eyes) met the inclusion criteria. The PGI consistently demonstrated significant IOP reduction across various studies and glaucoma subtypes. Mean IOP reductions ranged from 14.8 mmHg to 19.1 mmHg, depending on follow-up duration and patient characteristics. Complete success rates ranged from 38.4% to 75%, while qualified success rates were consistently high, reaching up to 93.2%. The PGI's unique design, featuring a smaller inner tube diameter (0.127 mm), is thought to contribute to a lower risk of hypotony compared to other non-valved implants. Three comparative studies with other GDDs reported similar success rates with potentially fewer early complications. Quality assessment revealed moderate-to-good quality evidence, with limitations including short follow-up periods and predominance of uncontrolled studies.
conclusionsThe PGI is emerging as a safe and effective surgical option for treating refractory glaucoma. Its smaller tube diameter and large surface area endplate contribute to efficient IOP control with a potentially lower risk of hypotony.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.